Impact Biomedical (IBO) Long-Term Investments (2022 - 2023)
Impact Biomedical (IBO) posted Long-Term Investments of $782000.0 for Q2 2023, little changed on a QoQ basis from $782000.0 in Q4 2022.
Impact Biomedical (IBO) Long-Term Investments (2022 - 2023) Analysis & Trends
Impact Biomedical's Long-Term Investments history runs 2 years deep, the most recent figure standing at $782000.0 for Q2 2023.
- Quarterly Long-Term Investments changed N/A year-over-year to $782000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $782000.0 (changed N/A YoY) and the FY2022 annual result came in at $782000.0, changed N/A from the prior year.
- Long-Term Investments was $782000.0 for Q2 2023 at Impact Biomedical, roughly flat from $782000.0 in the prior quarter.
- Across five years, Long-Term Investments topped out at $782000.0 in Q4 2022 and bottomed at $782000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Impact Biomedical | 47.44 Mn | 50.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 782,000.00 |
| Dec 31, 2022 | 782,000.00 |